Single-Cell Leadership Psomagen recently launched the Cellanome R3200, signaling a strong push in single-cell sequencing capabilities. This presents a sales opportunity to upsell high-throughput single-cell workflows, related reagents, and data analysis services to customers seeking cutting-edge cellular profiling.

Spatial Biology Expansion The partnership with OmicInsight for AI-powered high-resolution imaging and spatial biology co-detection positions Psomagen to offer integrated spatial omics services. This creates cross-sell potential to clients needing combined RNA/protein spatial analyses with sequencing.

Expanded Lab Footprint US-based CLIA and CAP certified labs with expanded offices to California indicate capacity growth and geographic reach. This supports targeted regional sales campaigns for clinical, academic, and pharma customers seeking nearby accredited sequencing services.

Diverse Platform Portfolio Psomagen’s capabilities span Sanger, Next-Gen Sequencing, microarrays, long-read technologies, and cellular/spatial workflows. There are cross-sell opportunities to existing biotech and academic clients who require end-to-end genomic services across multiple platforms.

Strategic Partnerships Recent collaborations with Agilent Technologies and 10x Genomics Xenium services integration, plus involvement in white papers, underscore a collaborative growth strategy. This can be leveraged to position bundled service packages and co-marketed offerings to enterprise accounts.